CD4 and neoplasm: In addition to expanded T cells targeting mKRAS driver mutations, treatment with ELI-002 2P frequently led to antigen spreading, with ex vivo-detectable expansion of CD4+ and CD8+ T cells targeting additional personalized tumor neoantigens similar to those discretely targeted by personalized vaccination.